Edgewise Therapeutics added to Best Ideas List at Wedbush

Wedbush added Edgewise Therapeutics to the firm’s Best Ideas List with multiple data readouts over the next 12 months and cash providing runway through 2027. The firm made no change to its Outperform rating or $31 price target, and tells investors that shares are up 58% year-to-date and despite the run-up, still sees an attractive entry point ahead of upcoming data readouts. Wedbush likes the odds of EDG-7500 demonstrating improvements on gradient reduction with more limited effects on ejection fraction based on preclinical data and sees interesting opportunities also approaching with sevasemten in Becker muscular dystrophy and Duchenne muscular dystrophy.